Neuritic (senile)
plaques are a hallmark of the pathology found in the brain of patients afflicted with Alzheimer's disease (AD). Neuritic plaques have been considered to be composed of an amyloid core surrounded by dilated neurites, although the use of anti-BIA4-protein antibody revealed the presence of diffuse plaques without a nuclearlike central mass or surrounding paired helical filament (PHF)-containing neuritic components. The presence of diffuse plaques without PHF-containing neuritic components strongly suggests that the formation of amyloid precedes the degeneration of neurites that surround amyloid. Diffuse plaques are thus considered to be an early marker of AD pathology.
In this article, we report that diffuse plaques, possible markers of early AD pathology, are immunostained with anti-protein kinase C(gll) [anti-PKC(BII)] antibodies. The PKC(@II)-immunoreacting components of the diffuse plaques extend from neurons embedded in the plaques. Immunoelectron microscopy of diffuse and mature neuritic plaques shows that PKC(j3II)-like immunoreactivity in the plaques is closely associated with membranous structures of fine neuronal processes apposed to the amyloid fibers. These fine neuronal processes are distinct from classical neurites found typically in mature neuritic plaques. Furthermore, biochemical analysis demonstrates that PKC abnormalities, but not other AD markers (ubiquitin and A66), were found in the neocortex of clinically nondemented individuals with cortical plaques. Therefore, the PKC alteration in neurons might be involved in the early pathophysiology of AD.
Understanding the early pathogenesis of Alzheimer's disease (AD) is of vital importance in developing a therapeutic strategy for intervention in this devastating disease. One clue might come from the study of diffuse plaques, suspected of being the earliest type of plaque in AD (Mann and Esiri, 1988; Tagliavini et al., 1988; Yamaguchi et al., 1988 Yamaguchi et al., ,1989 Giaccone et al., 1989; Ikeda et al., 1989; Ishii et al., 1989; Joachim et al., 1989; Motte and Williams, 1989; Ogomori et al., 1989) . Until recently, neuritic (senile) plaques have been considered to be composed of an amyloid core surrounded by dilated neurites (Wisniewski and Terry, 1973) . The use of anti-PIA4-protein antibody, however, revealed the presence of diffuse plaques without a nuclear-like central mass or surrounding paired helical filament (PHF)-containing neuritic components, changing the definition of neuritic plaques (Tagliavini et al., 1988; Yamaguchi et al., 1988 Yamaguchi et al., , 1989 Giaccone et al., 1989; Ikeda et al., 1989; Ishii et al., 1989; Joachim et al., 1989; Motte and Williams, 1989; Ogomori et al., 1989) . Anti-@/A4-protein antibody stains the amyloid core of classic plaques, burned-out plaques, the diffuse amyloid of primitive plaques, and diffuse plaques. The systematic study of Mann and Esiri (1988) demonstrated that brains of early-stage Down's syndrome patients contain diffuse plaques, those of intermediate-stage brains contain immature plaques, and those of advanced-stage brains contain mature plaques, suggesting that diffuse plaques are precursors of mature plaques. To shed light on the mechanisms of early plaque formation, we have examined diffuse plaques using immunoprobes for plaque-associated markers, including protein kinase C (PKC), which has recently been found, in nondemented and demented autopsy cases, to be associated with mature plaques . Diffuse plaques were found to be immunoreactive with antibodies against PKC@II), but not other markers, including other PKC isozymes, casein kinase II (CK-II), tau, and PHF, suggesting that the PKC@II) might be involved in an early stage of plaque formation. Furthermore, reduced levels of the particulate PKC(pI1) concentration and of PKC-dependent iI4,86,000 protein (P86) phosphorylation, but no increased levels of Alz-50 reactivity or anti-ubiquitin reactivity, were found in the neocortex of demented and nondemented autopsy cases with diffuse plaques. These results suggest that altered PKC reactions may be early changes in AD.
Materials and Methods
Biochemistry. Procedures for sample preparation and the in vitro phosporylation assay are described in a previous publication . PKCQ311) was quantified using Western blot as described previously . The anti-PKC(PI1) antibody was raised in rabbit against the keyhole limpet hemocyanin+onjugated peptide whose sequence was taken from the C-terminal portion of human PKC(PI1). The specificity and characterization of anti-PKC@II) antibody are given in a previous publication were adsorbed out by preincubation of the antibody with the PKC(@II) peptide but not with irrelevant peptides, suggesting the specificity of the staining. The C-terminal sequence of PKC(pI1) used to immunize rabbits is not found in any other PKC isozymes, further implying the specificity of the staining. Ubiquitin-and Alz-50-reactive material was quantified using an immunodot blot pro- A. An SMI-3 1 (neurofilamen+immunostained nvramidal neuron (iV) and neuritic processes (arrows) display extensive kKC(flII) immunolabeling around the cell dody and extenh diffusely into thd neuropil. B, The PKC@II)-labeled neuropil in a diffuse plaque shows the presence of anti-synaptophysin-labeled presynaptic terminals. C, Anti-SMI-3 lpositive neuritic processes (arrows), immersed in a PKC@II)-positive diffise plaque, are colocalized with PKC@II)-positive neuritic processes (arrows) in the diffuse plaque. D, Anti-PKC@II)-positive diffuse plaques do not show an association with RCA-l-positive micro&al processes (arrow) .
E, No anti-GFAP-positive processes can be observed in a PKC@II)-positive diffise plaque that is surrounding lipofuscin @)-containing neurons. F, Abundant GFAP-positive astrocytic processes (A) are observed in a PKC(@I)-positive mature plaque. G, Abundant RCA-l-positive microglial processes (M) are observed in relation to an anti-@A4-protein-positive mature plaque. H, No colocalization of neuritic and microglial processes is observed in a mature plaque. Scale bar, 15 Wm. cedure described previously (Love et al., 1988) . Anti-ubiquitin and Alzmalin for fewer than 10 d, while the right hemibrains were frozen for 50 are the generous gifts of Dr. A. Haas (NYU, Medical Center) and biochemical assay. The fixed brains were processed and examined for Dr. P. Davies (Albert Einstein College of Medicine), respectively. Fourplaques and tangles as described previously (Terry et al., 1987) . Four teen brains from clinically nondemented [73 t 9 yr; postmortem (PM) brains from nondemented cases contained moderate numbers of cortical time, 7 + 6 hr] cases and 15 brains from AD cases (76 k 7 yr; PM plaques. Five brains from AD cases contained few neocortical tangles, time, 5 k 4 hr) were used for the present study. Brains were sagittally whereas abundant hippocampal tangles and numerous cortical plaques cut, and the left hemibrains were fixed in 4% phosphate-buffered forconfirmed the diagnosis of AD. Immunohistochemistry. Laser confocal imaging was used to view the double-labeled sections. For immunohistochemistry, blocks from autopsy tissue of four controls (7 1 + 11 yr; PM time, 5 t 3 hr) and four AD cases (75 ? 10 yr; PM time, 6 f 1 hr) from the midfrontal cortex and the posterior hippocampus were fixed for 72 hr at 4°C in 2% paraformaldehyde (in PBS, pH 7.4). The tissue blocks were sectioned at 40 pm with an Oxford vibratome. The sections were double labeled overnight at 4°C with a mixture of the following antibodies or marker: (1) anti-PKC(PII)lanti-neurofilament (neuronal marker; SMI-3 1, Stemberger-Meyers Immunocytochemicals, Inc., Jarrettsville, MD), (2) anti-PKC@II)lanti-synaptophysin (presynaptic terminal marker; Boehringer Mannheim, Indianapolis, IN), (3) anti-PKC(PII)lbiotinylated RCA-1 (microglial marker; Vector Labs, Inc., Burlingame, CA), and (4) anti-PKC@II)/anti-alial fibrillarv acidic urotein (GFAP: astrocvtic marker: Boehhnger Mannheim, IndLanapolis; IN). Additional sections were do& ble immunolabeled with anti-amyloid PIA4 protein and anti-synaptophysin, SMI-3 1, or RCA-l. The sections were then incubated with a combination of secondary antibodies or avidin tagged with fluorescein isothiocyanate (FITC) or Texas Red (Vector Labs, Inc). The doublelabeled sections were transferred to gelatin-coated slides and mounted under glass coverslips with antifading medium (4% n-propyl gallate; Sigma Chemical Co., St. Louis, MO). The double-labeled vibratome sections were studied with the Bio-Rad MRC-600 laser confocal scanning microscope mounted on a Nikon Optiphot microscope. This system permits the simultaneous analysis of double-labeled samples in the same optical plane. The digitized video images of serial l-pm optical sections were stored on an optical disk for subsequent processing and analysis.
Electron microscopy. Vibratome sections were blocked with normal eoat serum (5%) and incubated overnight at 4°C with anti-PKWII)
(1: 'is). The se&o& were washed in PBS,&cubated with biotinylakd &at anti-rabbit IgG followed by avidin D-HRP (Vector ABC Elite), and reacted with diaminobenzidine (DAB; 0.2 mg/ml) in 50 mM Tris buffer (pH 7.4) with 0.001% H,O,. Control sections were incubated with preimmune serum. The immunostained sections were postfixed for 20 min in 1% OsO,, dehydrated, and flat embedded in epoxy/Araldite. Ultrathin sections were cut with a Reichert OM-U3 ultramicrotome and viewed with a 100 CX JEOL electron microscope.
Results
Confocal laser imaging of the control sections, reacted with anti-PKC(pII), showed immunolabeled neuronal perikarya and neuritic extensions of pyramidal cells in layers III and V of the frontal cortex and in the CA 1 to CA4 region of the hippocampus. In addition, occasional fine cellular processes were labeled in the neuropil and in the white matter. Some pyramidal cells in the AD cases were labeled with anti-PKC@II), and the prominently labeled amyloid plaques were distributed throughout the neuropil. Approximately 60-70% of the plaques were of the diffuse type and were mostly distributed in the superficial layers. The immature and mature neuritic plaques were also anti-PKC(fiI1) positive and were found in the deeper layers of the neocortex. In the hippocampus the anti-PKC@II)-immunoreactive plaques were distributed in the molecular layer of the dentate gyrus and in the entorhinal cortex. Anti-PKCUII) stained diffuse plaques as a fine granular or fibrillar mesh of cellular processes in the hippocampus and neocortex (Fig. 1A) . Neuronal perikarya were often found in the midst of the diffuse plaques (Fig. 1E) . Double-immunolabeled sections showed that the anti-PKC@II)-immunoreacting processes contained abundant antineurofilament (SMI-3 I)-positive fibers (Fig. 1 c) . Serial optical sections along the whole thickness of the diffuse plaques revealed a continuum between the PKC@II)ISMI-3 l-positive processes and the neuronal perikarya (Fig. 1A ). Sections were also double immunolabeled with anti-PKC@II)lanti-synaptophysin (presynaptic terminal marker). The neuropil harboring the PKC@II)-labeled diffuse plaques revealed the presence of anti-synaptophysin-labeled terminals (Fig. 1B) . The AD sections that were double labeled with anti-PKC(@II)lanti-GFAP and anti-PKC@II)IRCA-1 failed to show any association between the PKC@II)-positive processes in the diffuse plaques and cellular processes of astrocytes (Fig. 1E) or microglia (Fig. 1D ). In contrast, in immature and mature plaques, abundant numbers of astrocytic and microglial processes were found to be closely associated with the anti-PKC@II)-and anti-PIA4-protein-positive structures (Fig. IF-H) . At the ultrastructural level, the PKC@II)-positive material was closely associated with the membrane of fine cellular processes immersed in the plaques (Fig. 2) .
In vitro phosphorylation of P86 in the presence of PKC activators has been found to be diminished in the cytosolic fractions from AD cortex . In the present study, P86 phosphorylation was studied in four different groups of samples. The first group (N = 8) consisted of the nondemented cases without any plaques in the cortex. The second group (N = 4) contained the nondemented cases with some plaques in the cortex. The third group (N = 7) encompassed the AD patients with a moderate number of cortical plaques. The fourth group (N = 7) included the AD patients with numerous cortical plaques. The P86 phosphorylation in the second, third, and fourth groups was diminished as compared to the first group (one-way t test; p < 0.02, p < 0.001, p < 0.0005, respectively), with the trend toward the more pronounced changes in cases with more plaques (Fig. 3A ). The same cases were then reclassified according to tangle numbers. This time, the first group (N = 12) contained the nondemented cases without neocortical tangles. The second group (N = 5) included the AD samples with few neocortical tangles. The third group (N = 4) held the AD samples with a moderate number of tangles, and the fourth group (N = 5) had the AD samples with numerous tangles. Irrespective of the presence or absence of tangles, AD cases had lower levels of P86 phosphorylation than nondemented controls (Fig. 3B) . Therefore, decreased P86 phosphorylation correlated with plaque counts but not with neurofibrillary tangle counts. The diminished P86 phosphorylation was thus observed in nondemented cases with plaques.
In AD frontal cortex, PKC(PI1) is severely affected in that the particulate enzyme is diminished and the soluble enzyme is increased as detected by Western blots, and the number of neurons stained with anti-PKC(PI1) is diminished by 80% . The concentration of PKCQII) in the frontal cortex particulate fraction was studied and averaged for eight different classes of samples as described for P86 phosphorylation. The results for PKC(PI1) were qualitatively the same as for P86 phosphorylation (Fig. 3C,D) ; the PKC(BI1) alteration seemed to correlate with the presence of plaques and not with tangles. Other PKC isozymes in particulate fractions were not significantly affected in AD cortex.
Two other biochemical changes found in AD, increased levels of ubiquitin and Alz-50 antigen, were studied in eight classes of samples (Fig. 3E-H) . In contrast to P86 phosphorylation or anti-PKC(PI1) immunoreactivity, nondemented individuals with cortical plaques did not have altered levels of ubiquitin or Alz-50 antigen. The levels of these markers were higher in AD samples relative to control samples, irrespective of the presence or absence of tangles and plaques.
Discussion
The present study raises the possibility that an altered PKCdependent phosphorylation may be involved in an early stage ofplaque formation. There are two lines ofevidence that support . In vitro phosphorylation of P86 and the levels of particulate PKC(fiI1) are diminished in AD and in nondemented cases with plaques, whereas the levels of ubiquitin-and Alz-50-reactive material were not altered in nondemented cases with plaques. A and B, P86 phosphorylation expressed as the percentage of total phosphorylation; C and D, PKC@II) immunoreactivity; E and F, anti-ubiquitin immunoreactivity; G and H, Alz-50 reactivity. Various biochemical markers quantified as described in the previous publications Love et al., 1988; Masliah et al., 1990) are plotted for four categories of cases. The number of cortical plaques in a 100 x field is shown as - (0) this theory. First, diffuse plaques, which precede the appearance diffuse plaques. The levels of two other AD biochemical markof classical AD plaques, displayed anti-PKC(@II) immunoreacers, ubiquitin and Alz-50 antigen, were not elevated in nondetivity. Second, the reduced levels of particulate PKC(@I) and mented cases with cortical plaques, suggesting that, relative to the diminished PKC-dependent P86 phosphorylation were found PKC, they are involved in a later stage of AD pathogenesis. It in the cortex of clinically nondemented individuals with cortical is therefore possible that PKC-related alterations are age-asso-
The Journal of Neuroscience, September 1991, ff (9) ciated changes that may be involved in AD pathogenesis but molecular changes involved in plaque formation and in tangle precede AD symptoms. Thus, it is possible that the nondeformation are quite distinct. The involvement of phosphorymented samples with cortical plaques that we studied are from lation cascade reactions in both plaque and tangle formation, individuals who might have developed AD had they lived lonhowever, suggests the possible interaction of these two signal ger.
transduction pathways in AD (Saitoh et al., 199 1) . The finding A PKC-related alteration is correlated with neuritic plaque presented here that a PKC-related cascade is involved in the formation and not with neurofibrillary tangle formation. Alearly stage of the disease might help elucidate the hierarchy of though the identity of P86, the major PKC substrate, is yet to signal transduction changes in AD. be determined, P86 meets all of the biochemical criteria for Immunoelectron microscopic studies of diffuse plaques in the MARCKS (myristoylated alanine-rich C-kinase substrate) proneocortex and cerebellum have shown that these lesions contain tein (Stumpo et al., 1989 ). An anti-MARCKS protein antibody small, scattered bundles of amyloid among focally blurred memstains the neuritic plaques with the pattern indistinguishable branes of cell processes (Dickson et al., 1990; , from anti-PKC(PI1) staining (Saitoh et al., 199 1) . The other PKC 1990). The present study demonstrates that the amyloid-related substrate, GAP-43, has recently been localized to neuritic plaques structures in the diffuse plaques are contiguous with antias well (Masliah et al., 199 la) . The association of PKC-related PKC(PII)-and anti-neurofilament-positive processes derived changes with neuritic plaque formation is in contrast to our from neurons located near the diffuse amyloid deposits. This previous finding that the elevated levels of M, 60,000 protein result is consistent with previous electron microscopic studies (P60) phosphorylation are positively correlated with tangle with AD biopsy tissue that showed an intimate association benumbers, and that P60 phosphorylation levels in AD cases withtween the amyloid fibers and the plasma membrane of abnormal out tangles are comparable to those of normal cases (Saitoh et neuronal processes (Powers and Skeen, 1988) . Furthermore, al., 1988) . The identity of P60 awaits elucidation, although this studies in the aged monkey have pointed to an early neuritic protein is phosphorylated without PKC activation and is suginvolvement that precedes amyloid deposition (Cork and Price, gested to contain phosphotyrosine (Shapiro et al., 1991) . Fur-1990) . No microglial or astroglial processes were found to be thermore, tangles are immunostained with an anti-CK-II anassociated with the PKC@II)-positive processes in the diffise tibody but not with anti-PKC antibodies (Iimoto et al., 1990;  plaque, consistent with in vitro data that the majority of cultured Masliah et al., 1990) . Additionally, recent studies have suggested microglia or astroglia are anti-PKCQII) negative antigen, typically found in tangles, is associated with al., 199 1 b). Recent immunohistochemical and immunoelectron the PKC-independent phosphorylation of tau in AD (U&da et microscopic studies have described a loose association of mial., 1990; Lee et al., 199 1). Therefore, it is conceivable that the croglial processes with the diffuse plaques, but they were not specifically concentrated in the diffuse plaques (Itagaki et al., 1989; Rozemuller et al., 1989; Wisniewski et al., 1989; Cras et al., 1990; Mattiace et al., 1990) . How can we interpret the PKC association with neuritic plaque amyloid? The precursor of the major constituent of plaque amyloid (APP, amyloid PIA4-protein precursor) has been reported to be phosphorylated by PKC, and it has been suggested that the APP phosphorylation by PKC affects the metabolism of APP (Gandy et al., 1988; Buxbaum et al., 1990) . Alternatively, it is also possible that PKC regulates proteases responsible for APP degradation to amyloidogenic products. Because amyloidogenesis from APP requires its proteolytic degradation, altered PKC activity or localization might promote this process. Recently, we and others have demonstrated that stimulation of various cells increases APP release in the culture medium. For example, the treatment of PC 12 cells with basic fibroblast growth factor and NGF, possibly through PKC activation, increases the APP levels in the culture medium (Refolo et al., 1989; Schubert et al., 1989) . Stimulation of human platelets with thrombin, an activator of PKC, releases APP (Bush et al., 1990; Cole et al., 1990; Van Nostrand et al., 1990) . It has been reported that some isoforms of APP contain the protease inhibitor sequence (Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988) and are identical to the protease inhibitor protein nexin II (PN-II) (Oltersdorf et al., 1989; Van Nostrand et al., 1989) . Therefore, the stimulation of APP release around diffuse plaques from neurons, which is supported by elevated local levels or an increase in the specific activity of PKCQII) and stimulated by a still-unknown extracellular stimulus, may disturb the protease/ protease inhibitor balance and help amyloid deposits accumulate. Recent studies have demonstrated the accumulation of APP or its fragment in globular neurites within plaques adjacent to anti-/3IA4-reactive amyloid (Cole et al., 199 1, and references therein; Martin et al., 1991) .
In the present study, one previously unanswered question as to the localization of PKC(PI1) in the core of neuritic plaques was solved. Consistent with previously reported findings anti-PKC(PI1) immunostained the core portion of neuritic plaques, leaving the possibility that anti-PKC(PII)-reactive material might be deposited extracellularly. The components immunostained by anti-PKC@II) are different from the amyloid that is stained by anti-PIA4-protein or the classical neuritic components of plaques that are stained by anti-PKC(PI), anti-CK-II, anti-PHF, anti-ubiquitin, or Alz-50. The results in this article clearly demonstrate that the core portion of the plaque is not the mere mass of amyloid but is penetrated by neuronal processes immunopositive with anti-PKC(bI1) at the membrane (Fig. 4) . It is yet to be determined whether these fine neuronal processes penetrating into the amyloid deposit are a continuum of the surrounding neuritic components. The presence of anti-PKC@II)-positive neurons and processes in diffuse plaques suggests that fine neuronal processes that penetrate the core portion of classical neuritic plaques are from nearby neurons, whereas dilated axonal terminals and dendrites are from distant neurons (Probst et al., 1989) . The three-dimensional reconstruction of electron microscopic images is in progress in our laboratory to answer these questions.
In conclusion, PKC(@II) immunoreactivity is structurally associated with diffuse plaques. Classical neuritic alterations, most clearly detected by PHF markers and glial participation, are found only in neuritic plaques, not in diffuse plaques. Furthermore, the PKC-dependent phosphorylation of P86 and the PKC(@II) distribution are altered in the cortex of nondemented individuals with cortical diffuse plaques. Therefore, we suggest that a PKC aberration precedes clinical deficits in AD and correlates with neuritic plaque formation but not with neurofibrillary tangle formation. Future research toward the elucidation of mechanisms by which PKC participates in aberrant processing of the APP or amyloidogenesis will help in understanding the pathogenesis of AD and in developing therapeutic strategies to intervene with the progression of AD.
